NPPA Warns Companies Over Anti-Cancer Drug Price Compliance

The National Pharmaceutical Pricing Authority has directed state drug controllers to strictly monitor compliance with revised price caps for 137 anti-cancer medications. Manufacturers failing to implement these mandated reductions will face strict regulatory action. This move aims to make critical oncology treatments more affordable and accessible for cancer patients across the country.